Drug Details
General Information of the Drug (ID: DR7967) | ||||
---|---|---|---|---|
Name |
Entinostat
|
|||
Synonyms |
Entinostat; 209783-80-2; ms-275; SNDX-275; MS 275; MS-27-275; SNDX 275; Entinostat (MS-275); MS 27-275; pyridin-3-ylmethyl 4-((2-aminophenyl)carbamoyl)benzylcarbamate; MS275; pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate; UNII-1ZNY4FKK9H; Entinostat (MS-275,SNDX-275); 1ZNY4FKK9H; BAY 86-5274; N-(2-aminophenyl)-4-(N-(pyridin-3-ylmethoxycarbonyl)aminomethyl)benzamide; CHEMBL27759; pyridin-3-ylmethyl 4-(2-aminophenylcarbamoyl)benzylcarbamate; pyridin-3-ylmethyl {4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; NSC706995; BAY86-5274; NSC-706995; N-[[4-[(2-aminoanilino)-oxomethyl]phenyl]methyl]carbamic acid 3-pyridinylmethyl ester; pyridin-3-ylmethyl 4-((2-aminophenyl)carbamoyl)benzylcarbamate.; pyridin-3-ylmethyl N-({4-[(2-aminophenyl)carbamoyl]phenyl}methyl)carbamate; Carbamic acid, N-[[4-[[(2-aminophenyl)amino]carbonyl]phenyl]methyl]-, 3-pyridinylmethyl ester; Histone Deacetylase Inhibitor I; entinostatum; N-(2-aminophenyl)-4-[N-(pyridin-3-ylmethoxycarbonyl)aminomethyl]benzamide; Entinostat, free base; PubChem24433; Entinostat [USAN:INN]; MS-275 (Entinostat); MS-275 - Entinostat; 3-Pyridinylmethyl ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)carbamate; benzamide-type inhibitor, 3; Carbamic acid, ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)-, 3-pyridinylmethyl ester; cc-216; MLS006010183; Entinostat (JAN/USAN/INN); SCHEMBL148309; GTPL7007; DTXSID0041068; BDBM19410; AOB2570; EX-A038; SYN3039; CHEBI:132082; BCPP000155; HMS3426G07; HMS3648K12; HMS3654O11; HMS3744O17; ACT06782; AMY31163; BCP01824; MS-275,Entinostat,SNDX-275/; ZINC1488870; ABP000145; MFCD08272435; NSC756642; s1053; 3-pyridylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate; AKOS024262667; N-(2-Aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)aminomethyl]benzamide; AC-8968; BCP9000967; Carbamic acid, 3-pyridinylmethyl ester; CCG-208680; CS-0511; DB11841; Entinostat (MS-275, SNDX-275); NSC 706995; NSC-756642; SB16665; Carbamic acid, [[4-[[(2-aminophenyl)carbaonyl]phenyl]methyl]-, 3-pyridinylmethyl ester; NCGC00165833-01; NCGC00165833-02; NCGC00165833-03; NCGC00165833-04; NCGC00165833-13; AK158952; AS-17906; Carbamic acid, N-((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)-, 3- pyridinylmethyl ester; HY-12163; MS27-275; NCI60_038022; SMR004458705; MS-275, A HDAC1 and HDAC3 inhibitor; AB0021206; MS-275-27; ZK 244894; FT-0667871; SW219667-1; V2451; EC-000.2117; D09338; W-5370; 48247-EP2298768A1; 48247-EP2305643A1; 48247-EP2308868A1; 48247-EP2311494A1; 48247-EP2311840A1; 783M802; A815057; MS-275,Entinostat, SNDX-275, MS-27-275; SR-01000946382; Q1281020; SR-01000946382-1; W-201831; BRD-K77908580-001-02-1; BRD-K77908580-001-04-7; (pyridin-3-yl)methyl 4-(2-aminophenylcarbamoyl)benzylcarbamate; [4-(2-Amino-phenylcarbamoyl)-benzyl]-carbamic acid pyridin-3-ylmethyl ester; N-[[4-[[(2-Aminophenyl)amino]carbonyl]phenyl]methyl]-3-pyridinylmethyl ester, carbamic acid; N-[[4-[[(2-Aminophenyl)amino]carbonyl]phenyl]methyl]carbamic acid 3-pyridinylmethyl ester; 442532-99-2
Click to Show/Hide
|
|||
Molecular Type |
Small molecule
|
|||
Disease | Breast cancer [ICD-11: 2C60] | Phase 3 | [1] | |
Structure |
![]() |
Click to Download Mol2D MOL |
||
Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | ||||
Formula |
C21H20N4O3
|
|||
PubChem CID | ||||
Canonical SMILES |
C1=CC=C(C(=C1)N)NC(=O)C2=CC=C(C=C2)CNC(=O)OCC3=CN=CC=C3
|
|||
InChI |
1S/C21H20N4O3/c22-18-5-1-2-6-19(18)25-20(26)17-9-7-15(8-10-17)13-24-21(27)28-14-16-4-3-11-23-12-16/h1-12H,13-14,22H2,(H,24,27)(H,25,26)
|
|||
InChIKey |
INVTYAOGFAGBOE-UHFFFAOYSA-N
|
|||
CAS Number |
CAS 209783-80-2
|
|||
ChEBI ID | ||||
TTD Drug ID | ||||
DrugBank ID |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug | ||||||
Cladribine | Homo sapiens | Click to Show/Hide the Molecular Data of This NP | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [2] | |||||
Detail(s) |
Combination Info
![]() |
|||||
Molecule(s)
Regulation |
Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
|
Up-regulation | Cleavage | CASP8 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Cleavage | CASP9 | Molecule Info |
Pathway MAP
|
||
In-vitro Model | RPMI-8226 | CVCL_0014 | Plasma cell myeloma | Homo sapiens | ||
U266B1 | CVCL_0566 | Plasma cell myeloma | Homo sapiens | |||
MM1.R | CVCL_8794 | Plasma cell myeloma | Homo sapiens | |||
Experimental
Result(s) |
Combinations of cladribine and entinostat exhibit potent activity to induce anti-proliferative/anti-survival effects on MM cells via induction of cell cycle G1 arrest, apoptosis, and DNA damage response. |
Target and Pathway | ||||
---|---|---|---|---|
Target(s) | Histone deacetylase 1 (HDAC1) | Molecule Info | [3] | |
KEGG Pathway | Cell cycle | Click to Show/Hide | ||
2 | Notch signaling pathway | |||
3 | Thyroid hormone signaling pathway | |||
4 | Huntington's disease | |||
5 | Amphetamine addiction | |||
6 | Alcoholism | |||
7 | Epstein-Barr virus infection | |||
8 | Pathways in cancer | |||
9 | Transcriptional misregulation in cancer | |||
10 | Viral carcinogenesis | |||
11 | MicroRNAs in cancer | |||
12 | Chronic myeloid leukemia | |||
NetPath Pathway | TCR Signaling Pathway | Click to Show/Hide | ||
Panther Pathway | Wnt signaling pathway | Click to Show/Hide | ||
2 | p53 pathway | |||
Pathway Interaction Database | Regulation of nuclear SMAD2/3 signaling | Click to Show/Hide | ||
2 | Notch signaling pathway | |||
3 | E2F transcription factor network | |||
4 | Presenilin action in Notch and Wnt signaling | |||
5 | Signaling events mediated by HDAC Class I | |||
6 | Regulation of Telomerase | |||
7 | Glucocorticoid receptor regulatory network | |||
8 | Sumoylation by RanBP2 regulates transcriptional repression | |||
9 | Regulation of Androgen receptor activity | |||
10 | IL3-mediated signaling events | |||
11 | Validated nuclear estrogen receptor alpha network | |||
12 | Retinoic acid receptors-mediated signaling | |||
13 | Hedgehog signaling events mediated by Gli proteins | |||
14 | Regulation of nuclear beta catenin signaling and target gene transcription | |||
15 | Validated targets of C-MYC transcriptional repression | |||
16 | Regulation of retinoblastoma protein | |||
17 | Notch-mediated HES/HEY network | |||
Reactome | G0 and Early G1 | Click to Show/Hide | ||
2 | p75NTR negatively regulates cell cycle via SC1 | |||
3 | Formation of the beta-catenin:TCF transactivating complex | |||
4 | NOTCH1 Intracellular Domain Regulates Transcription | |||
5 | SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription | |||
6 | Constitutive Signaling by NOTCH1 PEST Domain Mutants | |||
7 | Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants | |||
8 | HDACs deacetylate histones | |||
9 | Deactivation of the beta-catenin transactivating complex | |||
10 | NoRC negatively regulates rRNA expression | |||
11 | RNA Polymerase I Transcription Initiation | |||
12 | Factors involved in megakaryocyte development and platelet production | |||
WikiPathways | SIDS Susceptibility Pathways | Click to Show/Hide | ||
2 | Notch Signaling Pathway | |||
3 | TGF beta Signaling Pathway | |||
4 | IL-6 signaling pathway | |||
5 | Apoptosis-related network due to altered Notch3 in ovarian cancer | |||
6 | Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer | |||
7 | Notch Signaling Pathway | |||
8 | Retinoblastoma (RB) in Cancer | |||
9 | Neural Crest Differentiation | |||
10 | TWEAK Signaling Pathway | |||
11 | Integrated Breast Cancer Pathway | |||
12 | Signalling by NGF | |||
13 | RNA Polymerase I, RNA Polymerase III, and Mitochondrial Transcription | |||
14 | Mitotic G1-G1/S phases | |||
15 | Factors involved in megakaryocyte development and platelet production | |||
16 | Cell Cycle | |||
17 | Androgen receptor signaling pathway |


